clinical trial · NCT07174427
Multi-center Study of TBI-1301 (INN: Mipetresgene Autoleucel; Mip-cel) in Patients With NY-ESO-1 Positive Synovial Sarcoma
Synovial SarcomasTBI-1301CyclophosphamideFludarabine
brief summary
The purpose of this study is to verify the safety and the efficacy of TBI-1301 for NY-ESO-1 expressing synovial sarcoma when administered following cyclophosphamide/fludarabine pre-treatment.
started
Jan 5, 2026
primary completion
Mar 1, 2032
completion
Mar 1, 2032
last updated
Feb 18, 2026
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol